HMO Research Network CERT III

HMO 研究网络 CERT III

• 批准号: 7489985
• 负责人: Richard Platt
• 金额: $ 99.86万
• 依托单位: HARVARD PILGRIM HEALTH CARE, INC.
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-01 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7489985
• 关键词: HMO; Research; Network; CERT; III

DESCRIPTION (Provided by the Applicant): The HMO Research Network CERT has provided important insights into the use, safety and effectiveness of therapies and requests funding to continue leveraging populations from a collaboration of diverse health plans as generalizable sources of therapeutics evidence and as vehicles for disseminating and implementing therapeutics best practices. Our sub-theme will be post-marketing safety, although we will also continue to be active in promoting physician and patient behavior change, the uses of information technology, and health policy to optimize the use of therapeutics. The HMORN CERT's core will consist of 13 health plans of the HMO Research Network, with total membership of 11 million. All have public domain research units strongly linked to their plans' senior leadership and delivery systems. The HMORN CERT will use a Virtual Data Warehouse to facilitate use of enrollment, pharmacy, diagnosis and procedure data, which provides the highest level of patient privacy while facilitating complex multi-site studies. All sites are also implementing electronic medical records, allowing a greater range of studies. The CERT will focus on studies requiring detailed data and/or the ability to engage providers and plan members. It will also provide critical infrastructure support for ongoing DEcIDE (AHRQ) and FDA contracts, and collaborate with the NCI-funded HMORN Cancer Research Network and NIH-funded Clinical Translational Science Centers. New core studies will include both substantive and methodological work: 1) longitudinal study of the safety and efficacy of drug-eluting coronary artery stents; 2) testing new methods for rapid prospective drug safety assessment by using routinely collected electronic health data; 3) use and safety of antipsychotic medications in children, focusing on abnormalities of glycemic control, and 4) risk of serious infection with use of new biological agents for rheumatoid arthritis in the elderly. These will be complemented by additional activities, including targeted collaborations with other CERTs. New activities will include: 1) A Health Plan Consortium for Public Health, involving larger health plans, to perform drug/vaccine safety studies requiring populations of tens of millions; 2) Studies impacting Medicare & Medicaid populations; 3) An Institute for Clinical and Economic Review to facilitate dissemination of cost effective therapies by informing rational coverage decisions; and 4) Education and dissemination programs.

描述（由申请人提供）：HMO 研究网络 CERT 提供了有关疗法的使用、安全性和有效性的重要见解，并请求资金继续利用不同健康计划合作中的人群作为治疗证据的普遍来源和作为治疗证据的载体传播和实施治疗最佳实践。我们的子主题将是上市后安全，尽管我们也将继续积极促进医生和患者行为的改变、信息技术的使用以及健康政策以优化治疗的使用。 HMORN CERT 的核心将由 HMO 研究网络的 13 个健康计划组成，会员总数为 1100 万。所有项目都设有与其计划的高级领导和交付系统密切相关的公共领域研究单位。 HMORN CERT 将使用虚拟数据仓库来促进登记、药房、诊断和程序数据的使用，从而提供最高级别的患者隐私，同时促进复杂的多站点研究。所有站点还都实施了电子病历，以便进行更广泛的研究。 CERT 将重点关注需要详细数据和/或吸引提供商和计划成员参与的能力的研究。它还将为正在进行的 DEcIDE (AHRQ) 和 FDA 合同提供关键基础设施支持，并与 NCI 资助的 HMORN 癌症研究网络和 NIH 资助的临床转化科学中心合作。新的核心研究将包括实质性和方法论工作：1）药物洗脱冠状动脉支架的安全性和有效性的纵向研究； 2）利用常规收集的电子健康数据测试快速前瞻性药物安全性评估的新方法； 3) 儿童抗精神病药物的使用和安全性，重点关注血糖控制异常；4) 老年人使用新生物制剂治疗类风湿性关节炎的严重感染风险。这些活动将得到其他活动的补充，包括与其他社区紧急响应小组 (CERT) 的有针对性的合作。新活动将包括： 1) 公共卫生健康计划联盟，涉及更大的健康计划，开展需要数千万人口的药物/疫苗安全研究； 2) 影响医疗保险和医疗补助人群的研究； 3) 临床和经济审查研究所，通过告知合理的承保决策，促进具有成本效益的疗法的传播； 4) 教育和传播计划。